JNJ logo Johnson & Johnson +
Johnson & Johnson
+

Johnson & Johnson (JNJ) Business News

Track Johnson & Johnson in real time with a live news feed covering Johnson & Johnson stock news, official press releases, company announcements, and an archive of historical Johnson & Johnson news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
7:00 AM | Thursday | May 21, 2026 Business Wire

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

News Thumbnail
9:00 AM | Tuesday | May 19, 2026 Business Wire

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

News Thumbnail
7:45 AM | Tuesday | May 12, 2026 Business Wire

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

News Thumbnail
8:00 AM | Monday | May 11, 2026 PRNewsWire

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

News Thumbnail
8:00 AM | Thursday | May 7, 2026 PRNewsWire

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

News Thumbnail
8:05 AM | Tuesday | May 5, 2026 PRNewsWire

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

News Thumbnail
8:05 AM | Tuesday | May 5, 2026 PRNewsWire

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

News Thumbnail
8:00 AM | Monday | May 4, 2026 PRNewsWire

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

News Thumbnail
8:02 AM | Thursday | Apr 30, 2026 Business Wire

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

News Thumbnail
8:03 AM | Monday | Apr 27, 2026 PRNewsWire

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

News Thumbnail

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

Business Wire

7:00 AM | Thursday | May 21, 2026

news photo
Loading...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced a collaboration with the Department of Health – Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, UAE, launching a global program to develop an open surgical intelligence network— establishing Abu Dhabi as the first node in a global infrastructure designed to accelerate artificial intelligence (AI) innovation for every stage of the surgery experience. Integrating Johnson & Johnson's Polyphonic™ o.

Read full article redirect
7:00 AM | Thursday | May 21, 2026

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced a collaboration with the Department of Health – Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, UAE, launching a global program to develop an open surgical intelligence network— establishing Abu Dhabi as the first node in a global infrastructure designed to accelerate artificial intelligence (AI) innovation for every stage of the surgery experience. Integrating Johnson & Johnson's Polyphonic™ o.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | May 19, 2026

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Portal Innovations, in partnership with the New Brunswick Development Corporation (DEVCO) and HELIX, today announced that Johnson & Johnson has secured naming rights to the Johnson & Johnson Exchange at the New Jersey Innovation Hub (NJIH), Powered by Portal Innovations. The collaboration reinforces Johnson & Johnson's longstanding leadership in advancing innovation, entrepreneurship, and the life sciences sector in New Jersey, one of the nation.

Read full article arrow
News Thumbnail
7:45 AM | Tuesday | May 12, 2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter.

Read full article arrow
News Thumbnail
8:00 AM | Monday | May 11, 2026

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

PRNewsWire

Oral presentations feature CAPLYTA ® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms 18 abstracts highlight J&J's leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings TITUSVILLE, N.J., May 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 18 abstracts featuring new and encore data from the Company's robust neuropsychiatry portfolio and pipeline will be presented at two upcoming scientific meetings: the American Psychiatric Association (APA) Annual Meeting (May 16-20, San Francisco) and the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (May 26-29, Miami).

Read full article arrow
News Thumbnail
8:00 AM | Thursday | May 7, 2026

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

PRNewsWire

Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don't believe antidepressants will help them reach remission Campaign draws on expertise of Mental Health America and elevates the voices of leading mental health advocates, including Kyle Long, television studio analyst, retired National Football League (NFL) player NEW BRUNSWICK, N.J., May 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel "fine" in depression care and empower patients to take the first step in moving beyond "good enough" by talking with their healthcare provider.

Read full article arrow
News Thumbnail
8:05 AM | Tuesday | May 5, 2026

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

PRNewsWire

JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to two or more systemic therapy classes JNJ-4804 is the first and only fixed dose co-antibody designed to deliver molecular synergy in IBD by blocking the complementary IL-23 and TNF pathways Data from Phase 2b DUET studies show potential to address a critical unmet need and support advancement to Phase 3 trials CHICAGO, May 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α), in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) that is refractory... Read more

Read full article arrow
News Thumbnail
8:05 AM | Tuesday | May 5, 2026

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

PRNewsWire

TREMFYA ® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to placebo at Week 24 First study of its kind in 20 years for this debilitating manifestation of Crohn's disease presented as late-breaking data at Digestive Disease Week 2026 CHICAGO, May 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 FUZION study evaluating TREMFYA® (guselkumab) in adults with active perianal fistulizing Crohn's disease (CD). At Week 24, TREMFYA demonstrated significantly higher rates of combined fistula remission, a highly stringent endpoint defined as complete external closure of draining fistulas and absence of fluid collection on MRI, compared to placebo.1 Remission in patients with this complicated manifestation remains difficult to achieve,... Read more

Read full article arrow
News Thumbnail
8:00 AM | Monday | May 4, 2026

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

PRNewsWire

CAPLYTA ® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the secondary endpoints for the adjunctive MDD therapies evaluated, CAPLYTA ® demonstrated no weight gain compared to placebo plus antidepressant therapy Featured in a late-breaking presentation at the 2026 NEI Spring Congress, analysis provides indirect comparisons to help inform treatment decisions in the absence of head-to-head clinical trials TITUSVILLE, N.J., May 4, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced findings from the first network meta-analysis (NMA) comparing CAPLYTA® (lumateperone) to FDA-approved atypical antipsychotics for add-on treatment of major depressive disorder (aMDD) in adults, drawing on data from 10 registrational randomized clinical trials.

Read full article arrow
News Thumbnail
8:02 AM | Thursday | Apr 30, 2026

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph J.
Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme. “Ryan's appointment underscores the deep bench of financial talent within Jo.

Read full article arrow
News Thumbnail
8:03 AM | Monday | Apr 27, 2026

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

PRNewsWire

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which pathogenic immunoglobulin G autoantibodies attach to and destroy red blood cells, leading to debilitating anemia IMAAVY is designed to target the underlying cause of warm autoimmune hemolytic anemia by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions Pivotal study showed rapid and durable hemoglobin response a and fatigue improvement b compared to placebo in patients with warm autoimmune hemolytic anemia SPRING HOUSE, Pa., April 27, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY® (nipocalimab-aahu),c confirming the urgent... Read more

Read full article arrow
News Thumbnail